Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination. 个人与社会观点：疫苗接种定量收益-风险评估的意义。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-10 DOI: 10.1080/14737167.2025.2572319

Taito Kitano, Daniel A Salmon, Matthew Z Dudley, Ian J Saldanha, Joseph F Levy, J Matthew Austin, David A Thompson, Lilly Engineer

{"title":"Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination.","authors":"Taito Kitano, Daniel A Salmon, Matthew Z Dudley, Ian J Saldanha, Joseph F Levy, J Matthew Austin, David A Thompson, Lilly Engineer","doi":"10.1080/14737167.2025.2572319","DOIUrl":"10.1080/14737167.2025.2572319","url":null,"abstract":"Introductions: The benefits and risks of each vaccine must be compared prior to their recommendation and again when new evidence emerges.Areas covered: A narrative scoping review was conducted by searching MEDLINE via PubMed on 8 October 2024 and 12 September 2025. The implications of benefit-risk assessments of vaccines are discussed. A quantitative benefit-risk assessment may be conducted from an individual perspective, which only considers direct health effects, or from a societal perspective, which considers both direct and indirect health effects (e.g. a reduction of transmissibility through community immunity). Whether the results of quantitative benefit-risk assessment of vaccination encompass an individual or societal perspective should be made clear as this changes the meaning for stakeholders. A societal perspective is fundamental to evaluating vaccine benefits and risks as a population. However, showing a beneficial impact from a societal perspective may not be sufficient motivation to vaccinate oneself or their children.Expert opinion: Benefit-risk assessments of vaccination from an individual perspective may be helpful for these individuals in their vaccine decision-making. Ideally, timely vaccine benefit-risk assessments from both societal and individual perspectives are conducted in parallel, and the results of both are clearly communicated to the public to aid in vaccine decision-making.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting. 西马鲁肽对美国现实世界中肥胖或超重患者一年医疗费用的影响

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-09 DOI: 10.1080/14737167.2025.2570688

Prachi Arora, Wojciech Michalak, Zhenxiang Zhao, Megan Fiasconaro, Yu Hong, Xin Zhao, Bríain Ó Hartaigh, Sara Alvarez, Angela Fitch

{"title":"Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.","authors":"Prachi Arora, Wojciech Michalak, Zhenxiang Zhao, Megan Fiasconaro, Yu Hong, Xin Zhao, Bríain Ó Hartaigh, Sara Alvarez, Angela Fitch","doi":"10.1080/14737167.2025.2570688","DOIUrl":"10.1080/14737167.2025.2570688","url":null,"abstract":"Background: Patients with obesity or overweight are at increased risk for obesity-related complications (ORCs), including cardiovascular disease. Treatment with once-weekly (OW) semaglutide 2.4 mg has demonstrated clinical efficacy, however its impact on healthcare resource utilization (HCRU) and costs warrants further investigation.Research design and methods: This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database. Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users. HCRU and medical costs estimates at 12-month follow-up, both all-cause and ORC-related, were compared between the two cohorts.Results: Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively. All-cause and ORC-related total medical costs were lower among patients treated with semaglutide 2.4 mg (11% and 15% lower, respectively), translating to an observed savings of $3,342 and $2,408 at 12 months.Conclusions: In patients with obesity or overweight, OW semaglutide 2.4 mg treatment was associated with decreased total medical HCRU and costs at 12 months.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation. 目前的挑战影响心理症状管理的患者接受CAR-T治疗或干细胞移植。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-08 DOI: 10.1080/14737167.2025.2572317

Amber Feng, Madhuri Gottam, Wil L Santivasi, Thomas W LeBlanc

{"title":"Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation.","authors":"Amber Feng, Madhuri Gottam, Wil L Santivasi, Thomas W LeBlanc","doi":"10.1080/14737167.2025.2572317","DOIUrl":"10.1080/14737167.2025.2572317","url":null,"abstract":"Introduction: Hematopoietic stem cell (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are crucial in the treatment of hematologic malignancies. While HSCT has been long established as a mainstay of the treatment of these diseases, CAR-T is a newer therapy with the potential to change the treatment landscape. Both cellular therapies are time and resource intensive, which has put stressors on patients that are unique from those associated with other forms of oncologic treatment.Areas covered: In this review, we discuss the current state of knowledge of psychological symptoms associated with HSCT and CAR-T and their management. In addition, we discuss the models of patient reported outcomes (PROs) used to perform this research. We performed a literature review on PubMed using keywords including 'palliative care, palliative care integration, hematologic malignancy, patient reported outcome, psychological care, and quality of life.' We included papers published before 1 April 2025.Expert opinion: We propose further investigations into integrated models of oncologic and palliative care teams and their efficacy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019-2025): a systematic review. 撒哈拉以南非洲地区艾滋病毒预防干预措施的成本效益（2019-2025）：系统回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-07 DOI: 10.1080/14737167.2025.2570695

Christopher Mugari, Akim Tafadzwa Lukwa, Denis Okova, Plaxcedes Chiwire, Mickaël Hiligsmann

{"title":"Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019-2025): a systematic review.","authors":"Christopher Mugari, Akim Tafadzwa Lukwa, Denis Okova, Plaxcedes Chiwire, Mickaël Hiligsmann","doi":"10.1080/14737167.2025.2570695","DOIUrl":"10.1080/14737167.2025.2570695","url":null,"abstract":"Introduction: This systematic review synthesizes recent evidence on the cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (SSA), where over 70% of the global HIV burden resides.Methods: Following PRISMA 2020 guidelines, we searched five databases (2019-2025) for full economic evaluations of HIV prevention in SSA. Studies were assessed using CHEERS 2022 and Drummond checklists. Costs were adjusted to 2024 USD and compared to GDP per capita thresholds. Results were synthesized narratively.Results: 30 studies were included; 28 used model-based designs, 2 used trial or cohort data. The most frequently evaluated interventions were PrEP (n = 7), PMTCT (n = 4), and HIV testing innovations (n = 3). Oral PrEP was the dominant form, though two studies evaluated long-acting injectable PrEP. Interventions were considered cost-effective if the Incremental Cost Effectiveness Ratio (ICER) was below 1-3 times GDP per capita. For example, dolutegravir-based PMTCT had an ICER of USD109/DALY averted. Peer-delivered self-testing and maternal HIV screening in immunization clinics showed strong economic efficiency. Few studies incorporated real-world data on medication adherence, drop-out or service delivery costs.Conclusions: Targeted, integrated HIV prevention strategies are cost-effective in SSA. Future studies should improve use of empirical adherence and implementation data and expand focus to underrepresented populations and regions.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-13"},"PeriodicalIF":1.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing the economics of prevention: emerging methods and approaches. 推进预防经济学：新方法和途径。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-07 DOI: 10.1080/14737167.2025.2570689

Sabine E Grimm, Ghislaine van Mastrigt, Mickaël Hiligsmann

{"title":"Advancing the economics of prevention: emerging methods and approaches.","authors":"Sabine E Grimm, Ghislaine van Mastrigt, Mickaël Hiligsmann","doi":"10.1080/14737167.2025.2570689","DOIUrl":"10.1080/14737167.2025.2570689","url":null,"abstract":"Introduction: There is global consensus on the critical role of prevention in improving population health and reducing long-term healthcare costs. However, investment in prevention remains comparatively limited. With governments increasingly prioritizing prevention, this may be poised to change.Areas covered: To estimate the economic value of preventive health technologies and support their prioritization for a sustainable healthcare system, we propose three essential themes for economic evaluation: recognizing the value of prevention, estimating its uncertain benefits, and enabling system-level change. We outline key objectives within each theme and highlight emerging methods and approaches to address them.Expert opinion: The key challenge ahead lies in translating these methodological advancements into policy-relevant evidence that supports effective and sustainable prevention strategies. By integrating interdisciplinary perspectives and advancing economic evaluation approaches, we can help ensure prevention receives the recognition and investment needed to foster healthier, more resilient societies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer. 对转移性乳腺癌治疗的NICE评估中使用的经济评估的方法学方面的回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-27 DOI: 10.1080/14737167.2025.2537191

Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus van Hulst

{"title":"A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer.","authors":"Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus van Hulst","doi":"10.1080/14737167.2025.2537191","DOIUrl":"10.1080/14737167.2025.2537191","url":null,"abstract":"Introduction: Methodological choices need to be made during model development. These choices can influence the outcome of a National Institute for Health and Care Excellence (NICE) assessment.Areas covered: This review aims to identify, assess, and describe possible trends within the methodological aspects of economic evaluations used in NICE assessments of treatments for metastatic breast cancer (mBC). The NICE website was searched to identify technology appraisals submitted between 1 January 2009, and 31 December 2023. In this review methodological aspects are analyzed and discussed in three clusters - input data, model settings, and model outcomes - across the following characteristics: clinical trial information, quality-of-life measures, treatments used, model structure, health states, time horizon, threshold applied, and the NICE recommendations. This review provides a reference for stakeholders who want to understand previous NICE assessments of treatments for mBC, and the settings used in those, which can optimize decisions during model development.Expert opinion: Uniformity in the methodological choices made during model development and the economic evaluations can increase transparency, increase comparability, and reduce complexity of the NICE assessment.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1149-1157"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The economic benefits of fracture prevention. 预防骨折的经济效益。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI: 10.1080/14737167.2025.2539838

Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann

{"title":"The economic benefits of fracture prevention.","authors":"Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann","doi":"10.1080/14737167.2025.2539838","DOIUrl":"10.1080/14737167.2025.2539838","url":null,"abstract":"Introduction: Osteoporosis-related fractures represent a significant and growing public health concern, especially in aging populations. Despite the availability of effective treatments, significant care gaps persist in both primary and secondary prevention.Areas covered: This narrative review synthesizes key findings from economic evaluations examining the cost-effectiveness of pharmacological and non-pharmacological therapies, fracture liaison services (FLS), and FRAX®-based intervention thresholds. Relevant literature was reviewed, including systematic reviews, country specific studies, and emerging data on novel technologies. The evidence consistently demonstrates that fracture prevention strategies are cost-effective across diverse healthcare settings. Pharmacological monotherapy and sequential regimens have shown favorable economic profiles, while FLS programs, although resource-intensive, significantly reduce re-fracture rates and associated costs. Intervention thresholds should be derived clinically, with health economic modeling used to evaluate their cost-effectiveness so as to guide rational, risk-based treatment strategies.Expert opinion: Health economic evaluations are increasingly enabling the development of osteoporosis treatment strategies, highlighting the strong cost-effectiveness potential of these interventions. However, challenges remain including heterogeneity in analytical approaches, under-representation of low- and middle-income countries, and limited incorporation of real-world (adherence) data. Maintaining methodological consistency, expanding region-specific data, and evaluating emerging technologies with robust economic frameworks are essential steps toward achieving globally equitable and cost-effective osteoporosis care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1143-1148"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis. 保加利亚患者一线奥西替尼有效性的真实世界证据：回顾性分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-20 DOI: 10.1080/14737167.2025.2535636

Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova

{"title":"Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis.","authors":"Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova","doi":"10.1080/14737167.2025.2535636","DOIUrl":"10.1080/14737167.2025.2535636","url":null,"abstract":"Background: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved as a first-line treatment against non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. Herein, we perform a retrospective analysis of real-world data on first-line osimertinib treatment among Bulgarian patients with NSCLC, comparing treatment outcomes to FLAURA results.Research design and methods: Patient data were obtained from electronic health records over a 4-year period. Baseline characteristics and endpoints (progression-free survival [PFS], objective response rate [ORR], and clinical benefit rate [CBR]) were compared. Iterative proportional fitting was performed to balance patient characteristics prior to survival analysis.Results: A total of 365 patients on first-line osimertinib were included. Partial responses were more frequent in the RWE cohort (24% vs 13%), while the opposite was noted for stable disease (63% vs 80%). Complete response frequency was comparable (2% vs 1%). The ORR was higher in the real world compared to in FLAURA (26% vs 14%), whereas CBR was slightly higher in the trial (89% vs 94%). The real-world PFS was higher than reported in FLAURA (19.1 vs 18.9 months), with more favorable outcomes in the RWE cohort beyond 18 months.Conclusion: RWE closely aligns with FLAURA results, suggesting even greater benefit of first-line osimertinib in the real-world setting.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1231-1237"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies. 肺炎球菌疾病的部门间成本：对部分经济评估研究的系统回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-08-03 DOI: 10.1080/14737167.2025.2542285

Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus

{"title":"Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies.","authors":"Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus","doi":"10.1080/14737167.2025.2542285","DOIUrl":"10.1080/14737167.2025.2542285","url":null,"abstract":"Introduction: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs.Methods: Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed.Results: Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients' age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported.Conclusions: Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies.Registration: PROSPERO (CRD42023417042).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1195-1210"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations. 自行车道对提高人口体育活动水平的价值：经济评估的系统回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-08-05 DOI: 10.1080/14737167.2025.2542289

Luiz F Andrade, Bisola Osifowora, Emma Frew

{"title":"The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations.","authors":"Luiz F Andrade, Bisola Osifowora, Emma Frew","doi":"10.1080/14737167.2025.2542289","DOIUrl":"10.1080/14737167.2025.2542289","url":null,"abstract":"Background: Active travel (AT), particularly cycling, is increasingly recognized as a public health strategy to promote physical activity and prevent non-communicable diseases (NCDs). Given the substantial investments required to build cycling infrastructure, economic evaluations are essential to inform policy and efficient funding decisions. This systematic review aims to identify and assess economic evaluations of cycleway infrastructure, with particular emphasis on the methodological approaches employed.Methods: A systematic review was conducted using databases including PubMed, EconLit, Business Source Premier, CINAHL Plus, and MEDLINE. Eligible studies focused on cycling-specific infrastructure, reported both costs and benefits, and included a comparator. Data were extracted on evaluation type, costs, benefits, perspective, and time horizon. Study quality was assessed using the Drummond checklist, and findings were synthesized narratively, following PRISMA guidelines.Results: Eight studies met the inclusion criteria, using cost-benefit analysis or cost-effectiveness analysis. Interventions ranged from single cycle tracks to complex networks. Most studies were hypothetical and relied on secondary data and modeling assumptions. All reported positive economic returns. Equity impacts were rarely considered, and substantial methodological variability was observed.Conclusion: Cycling infrastructure appears to demonstrate economic value for society. However, methodological inconsistencies and data limitations remain considerable and limit comparability and generalizability of findings.Registration: PROSPERO Protocol:(CRD420251005334).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1183-1194"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0